Studies included in systematic review
| Study (country) | n (male) | Mean size | Mean follow-up | Mean age | Location | Local recurrence | Metastases | Risk of bias* |
| Bowe et al3 (UK) | 49 (45) | 23.5 mm (median) | 22.4 months | 80 (median) | 32 scalp 5 forehead 3 ear 3 cheek 2 nose 2 lower leg 1 temple 1 lower lip | 6/41 (6 clear margins) | 1/41 (1 death) | Moderate |
| 7/41 | ||||||||
| Cesinaro et al4 (Italy) | 7 | – | 13 months | – | – | 3/7 | 0/7 (0 deaths) | Low |
| 3/7 | ||||||||
| Helbig et al5 † (Germany) | 25 (19) | – | – | 78 | 3 head/neck 2 shoulder | 0 deaths from 1 MiTF-expressing PDS case with follow-up | High | |
| Jasper et al6 (Canada) | 20 | – | – | – | – | 6/20 | 2/20 | Moderate |
| Klein et al7† (Germany) | 28 (23) | – | – | 80 (median) | 26 head/neck 2 shoulder | 5/28 | Moderate | |
| Lonie et al2 (Australia) | 27 (23) | – | 46.4 months | 79.27 | 17 scalp 7 face 2 ear 1 torso | 2/26 (1 positive, 1 close margin) | 1/27 (1 death) | Low |
| 3/27 | ||||||||
| Miller et al8 (UK) | 32 (27) | 25 mm | 24 months (median) | 81 | 22 scalp 4 forehead 2 ear 2 temple 1 eyebrow 1 forearm | 8/29 (7 incomplete removal) | 3/29 (0 deaths) | Moderate |
| 8/29 | ||||||||
| Miller et al9 (USA) | 17 | – | – | – | – | 2/2 | 0/2 | High |
| 2/2 | ||||||||
| Müller et al10 (Germany) | 19 (15) | 6.75 cm2 | – | 81.16 | 16 head 2 face 1 upper extremity | 2/19 | 0/19 | High |
| 2/19 | ||||||||
| Nonaka and Bishop11 (Japan) | 34 | – | >2 years | – | – | 1/34 death (positive margin, metastasis) | Moderate | |
| Persa et al12 (Europe) | 92 (80) | 20 mm | 18 months | 81 (median) | 76 scalp 9 trunk 7 extremities | 18/92 | 8/92 | Low |
| 26/92 | ||||||||
| Ríos-Viñuela et al13‡ (Spain) | 16 (14) | 25.63 mm (n=15) | 25.88 months | 80.43 | 10 scalp 1 forehead 2 nose 2 ear 1 temple | 12/16 (8 positive margins) | 3/16 (2 deaths) | Low |
| 12/16 | ||||||||
| Tardío et al14 (Spain) | 18 (9) | 22 mm | 40 months | 81 | 9 scalp 5 forehead 1 nose 1 eyebrow 1 cheek 1 temple | 3/15 (3 positive margins) | 3/15 (3 deaths) | Moderate |
| 5/15 | ||||||||
| Thum et al15 § (UK) | 3 (3) | 31.67 mm | 3 months | 79 | 2 scalp 1 temple | 0 recurrences or deaths from 2 pseudovascular PDS cases with follow-up | Moderate | |
| Wang et al16 ¶ (USA) | 6 (6) | 11 mm | 48.6 months | 61 | 3 scalp 2 temple 1 ear | 4 recurrences and 4 deaths from 6 metastatic PDS cases | Low | |
| Total | 331 (199/237 male) | 21.47 mm | 13–46.4 months | 80.64 | 156/218 scalp 33/237 face | 50/251 | 18/252 (6/174 deaths) | 5 low 7 moderate 3 high |
| 56/232 | ||||||||
*Rated using the modified Newcastle-Ottawa Scale for case series from Haffar et al.21
†Results not pooled with others due to overlap with cohort from Persa et al.12
‡Results not pooled with others as study cohort was primarily composed of recurrent PDS referred from other institutions.
§Results not pooled with others as study examines a subset cohort from Miller et al8 of pseudovascular PDS.
¶Results not pooled with others as study examined metastatic PDS only.
MiTF, Microphthalmia-associated transcription factor; PDS, pleomorphic dermal sarcoma.